Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Recruiting · Phase 1 · NCT06966024
Conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
At a glance
- Research payments reported, 2025
- $130,413
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- DCC-2812 (drug)
- Dates
- Started 2025-08-27; completion 2029-02
- Results posted
- Not yet
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
From ClinicalTrials.gov, last updated 2026-08-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $130,413 in research payments for this study in 2025 (24 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bicky Thapa, M.D. Medical Oncology · Boston, MA
- Ildefonso I. Rodriguez-rivera, M.D. Hematology & Oncology · San Antonio, TX
- Andrae L. Vandross, M.D. Medical Oncology · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- New Experimental Therapeutics of San Antonio LLC $129,243
- Dana-Farbermass General Brigham Cancer Center Inc $1,170
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.